Bioresponsive nanoplatforms for imaging and therapy of cardiovascular diseases

Cardiovascular diseases (CVDs) are still the first cause of death worldwide. Conventional small molecular diagnostic and therapeutic agents generally show limited in vivo detection sensitivity and efficacies, due to their non‐targeting distribution and/or low accumulation at diseased sites. New stra...

Full description

Saved in:
Bibliographic Details
Published inView (Beijing, China) Vol. 3; no. 1
Main Authors Li, Chenwen, Wu, Peng, Dou, Yin, Li, Qi, Zhang, Jianxiang
Format Journal Article
LanguageEnglish
Published Beijing John Wiley & Sons, Inc 01.01.2022
Wiley
Subjects
Acids
Atherosclerosis
bioresponsive materials
Blood clots
cardiovascular diseases
drug delivery
Drugs
Enzymes
Heart attacks
imaging
Medical diagnosis
Nanomaterials
Nanoparticles
Stroke
Thrombosis
Tumors
Online AccessGet full text

Cover

More Information
Summary:Cardiovascular diseases (CVDs) are still the first cause of death worldwide. Conventional small molecular diagnostic and therapeutic agents generally show limited in vivo detection sensitivity and efficacies, due to their non‐targeting distribution and/or low accumulation at diseased sites. New strategies are required to better address the unmet need for the management of CVDs. Bioresponsive nanoplatforms with excellent triggerable release profiles and desirable targeting capability have demonstrated intriguing prospects in detection, prevention, and therapy of CVDs. This review summarizes recent advances in bioresponsive nanoplatforms responsive to biochemical stimuli, such as pH, redox potential, reactive oxygen species, enzymes, and adenosine triphosphate. We highlight the applications of different bioresponsive nanoplatforms for imaging and therapy of typical CVDs, including myocardial infarction, atherosclerosis, thrombosis, ischemic stroke, and heart failure. Finally, existing challenges and future perspectives are also discussed, with respect to the development and translation of bioresponsive nanoplatforms for CVDs. Cardiovascular diseases (CVDs) are still the first cause of global death. This review summarizes the applications of different bioresponsive nanoplatforms for imaging and therapy of typical CVDs, including myocardial infarction, atherosclerosis, thrombosis, ischemic stroke, and heart failure. Existing challenges and future perspectives are also discussed.
ISSN:2688-3988
2688-268X
2688-268X
DOI:10.1002/VIW.20200137